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Abstract
Subgroup analysis is a frequently used tool for evaluating heterogeneity of treat-
ment effect and heterogeneity in treatment harm across observed baseline patient
characteristics. While treatment efficacy and adverse event measures are often re-
ported separately for each subgroup, analyzing their within-subgroup joint distribu-
tion is critical for better informed patient decision-making. In this paper, we describe
Bayesian models for performing a subgroup analysis to compare the joint occurrence
of a primary endpoint and an adverse event between two treatment arms. Our ap-
proaches emphasize estimation of heterogeneity in this joint distribution across sub-
groups, and our approaches directly accommodate subgroups with small numbers of
observed primary and adverse event combinations. In addition, we describe several
ways in which our models may be used to generate interpretable summary measures
of benefit-risk tradeoffs for each subgroup. The methods described here are illustrated
throughout using a large cardiovascular trial (N = 9, 361) investigating the efficacy
of an intervention for reducing systolic blood pressure to a lower-than-usual target.
Keywords: Heterogeneity of treatment effect; patient-centered outcomes research; person-
alized medicine; benefits and harms trade-off
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1 Introduction
Both treatment effectiveness and treatment safety often vary according to patient sub-
populations that are defined by observable baseline patient characteristics. Although the
importance of evaluating the consistency of treatment effectiveness is often recognized
when conducting subgroup analyses, heterogeneity in treatment safety is not examined
as frequently. Moreover, when heterogeneity in treatment safety is addressed, such sub-
group analyses are typically performed separately from the heterogeneity of treatment
effect (HTE) analysis. While useful for addressing question of HTE and heterogeneity in
adverse effects, such separate analyses ignore potentially important relationships between
primary outcomes and safety outcomes. Dependencies between these two outcomes can
substantially alter the risk-benefit considerations when compared with just analyzing their
marginal distributions. In order to improve the relevance of subgroups analysis for assess-
ing variation in patients’ risk-benefit profiles, it is critical to focus on examining differences
in joint patient outcomes (Evans & Follmann (2016)) within key patient sub-populations.
Over the course of a clinical trial, patients experience a collection of outcomes of which
some may be related to treatment benefit while others may be related to an adverse effect of
treatment. From a patient-level perspective, a risk-benefit assessment involves examining
the potential set of outcomes that would occur when taking a proposed treatment versus
the potential set of outcomes that would occur under a control treatment. A treatment
may be considered superior to the control if the likely set of outcomes under treatment is
better than the likely set of outcomes under the control. In this article, we focus on the
frequently occurring case where the recorded set of patient outcomes includes a time to some
primary event and a binary indicator of whether or not a treatment-related adverse event
occurred at some point during the period of patient follow-up. Similar ways of addressing
both efficacy and safety have been proposed, for example, in the analysis of dose-finding
studies (Padmanabhan et al. (2012)), but to our knowledge, little work has been done in
the context of bivariate subgroup analysis.
Methods based on Bayesian hierarchical models have a number of advantages when
conducting subgroup analyses (Jones et al. (2011) or Henderson et al. (2016)), and many
of these advantages should be more strongly felt when extending such methods to bivariate
2
patient outcomes. It is well-recognized that subgroups defined by multivariate patient
characteristics often have many subgroups with small within-subgroup samples sizes. This
leads to very noisy estimates of subgroup-specific quantities - a phenomenon which is likely
to be further exacerbated when examining the joint distribution of patient outcomes. A
key advantage of a Bayesian approach coupled with hierarchical modeling is that subgroup-
specific parameter estimates are partially driven by data in that particular subgroup and
partially driven by patient outcomes in all the other subgroups. Allowing such “borrowing
of information” across subgroups leads to shrunken estimates of subgroup parameters which
frequently improves both the accuracy and stability of estimation (Efron & Morris (1973)).
In addition to simply generating more stable shrinkage estimates, Bayesian hierarchical
models allow one to specify how subgroup parameters are related to one another. In this
article, we focus on two approaches for modeling the relationships between the subgroup
parameters (a saturated and an additive model), but many other alternatives could easily
be incorporated into our framework for bivariate subgroup analysis.
In this article, our main goal is to harness the advantages of Bayesian modeling to de-
scribe the joint distribution of a primary and an adverse event across patient subgroups.
To this end, we outline a within-subgroup parametric model which assumes an exponen-
tial distribution for both adverse event-free and adverse-event-occurring survival. While
such a parametric assumption may not be strictly correct, our assumption is that survival
follows an exponential distribution within each subgroup rather than the entire popula-
tion represented by the trial. We argue that this is a sensible choice given the potentially
small number of patients within any particular subgroup. Moreover, our approach for di-
rect modeling of patients’ joint distributions provides great flexibility to analyze patients’
risk-benefit tradeoffs from a variety of perspectives. For example, we demonstrate how our
model may be used to assess heterogeneity with respect to either a composite outcome
which weights adverse event-free and adverse event-occurring survival differently, and how
our model may be used to evaluate heterogeneity with respect to a treatment effect based
on the probability of achieving an improved outcome.
This paper has the following organization. In Section 2, we begin by describing our
motivating example - the SPRINT trial, and we describe both the subgroups to be analyzed
3
and the primary and adverse events measured in this large clinical trial. In Section 3, we
outline our parametric model for the joint distribution of the time-to-a-primary event and
a binary adverse event, and we discuss its use in the context of bivariate subgroup analysis.
Section 4 describes a general approach for specifying a prior distribution for the model
parameters of Section 3, and we describe three particular ways of modeling the distribution
of these parameters. In Section 5, we detail several interpretable measures of variation in
patients’ risk-benefit profiles. Here, we describe how our Bayesian framework may be used
to make inferences about such measures. Patient outcomes from the SPRINT trial are used
to illustrate the use of these measures. Section 6 discusses the use of model diagnostics
and model comparison, and Section 7 concludes with a brief discussion.
2 The SPRINT Trial
The Systolic Blood Pressure Intervention (SPRINT) trial (The SPRINT Research Group
(2015)) was a large trial investigating the use of a lower-than-usual systolic blood pressure
target among individuals deemed to be at increased cardiovascular risk. Specifically, the
trial was designed to compare an intensive treatment (a systolic blood-pressure target of
less than 120 mm Hg) versus the standard treatment (a systolic blood-pressure target of
less than 140 mm Hg). In total, 9361 individuals were enrolled in the trial, and each trial
participant was classified as being at increased cardiovascular risk but without diabetes
and had a systolic blood pressure greater than 130 mm Hg. Of the 9361 trial participants,
4678 were randomized to the intensive treatment arm while 4683 were randomized to the
standard treatment arm.
In the SPRINT trial, patient outcomes were recorded as a composite outcome where
a primary event (PE) was said to occur if any one of the following five events took place:
death from cardiovascular causes, stroke, myocardial infarction, acute coronary syndrome
not resulting in myocardial infarction, or acute decompensated heart failure. At the con-
clusion of the trial (median follow up time of 3.26 years), a total of 562 PEs had occurred
with 243 PEs occurring in the intensive treatment arm and 319 PEs occurring in the
standard treatment arm. Based on these differences in the distribution of the PEs across
treatment arms, the intervention was determined to have an overall benefit (an estimated
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log-hazard of 0.75, confidence interval: [0.64, 0.89]). In addition to the primary outcome,
participants were also monitored for the occurrence of serious adverse events (SAEs). The
most common SAEs included acute kidney injury or acute renal failure, injurious fall, elec-
trolyte abnormality, syncope, and hypotension. Each of the observed SAEs were classified
according to whether or not they were possibly or definitely related to the intervention.
Of the observed treatment-related SAEs, 220 individuals in the intensive treatment group
experienced a treatment-related SAE while only 118 participants in the standard treatment
group experienced a treatment-related SAE.
While the marginal occurrence of SAEs in each treatment arm suggests that the stan-
dard treatment carries a lower risk of SAEs, the joint occurrence of primary events and
SAEs may be more informative from a patient-centered perspective. That is, the risk-
benefit tradeoffs involved in choosing a treatment strategy are more apparent when the
likelihood of each PE-SAE combination can be examined. This can be particularly impor-
tant in cases where the dependence pattern between the PE and SAE differs substantially
across treatment arms.
Standard Treatment Intensive Treatment
SAE No SAE SAE No SAE
PE 18 301 30 213
No PE 100 4264 190 4245
Table 1: SPRINT trial: joint counts for primary events (PE) and serious adverse events
(SAE) that were classified as possibly or definitely related to the intervention.
Table 1 shows the number of joint occurrences of PEs and treatment related SAEs in
the SPRINT trial. As evidenced by the counts in Table 1, most patients in both treatment
arms remained free from both PEs and SAEs over the course of the trial. A notable
difference between the two treatment arms is the difference in the proportion of PEs that
were accompanied by an SAE. However, only examining the joint counts of PEs and SAEs,
of course ignores the timings of the PEs. In the next section, we outline a subgroup-specific
parametric model for describing the joint distribution of a time-to-event primary outcome
and a binary safety outcome.
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3 Bivariate Subgroup Analysis
3.1 Data Structure and Summary Statistics
We assume that n patients have been enrolled in a randomized clinical study where patients
are monitored to determine whether they experience either a primary event (PE) or an
adverse event (AE) (or both). For the ith individual in the study, Ti denotes the time-
to-failure for the PE of interest. We observe Yi = min{Ti, Ci} and an event indicator
δi = I(Ti ≤ Ci) where Ci denotes time-to-censoring and I(·) denotes the indicator function.
In addition to observing the pair (Yi, δi), we observe an indicator Wi of whether or not
patient i experienced at least one AE during the study. That is, Wi = 1 if patient i
experienced at least one AE and Wi = 0 otherwise. We let Ai = 1 denote that patient i
was assigned to the treatment arm, and we let Ai = 0 denote that patient i was assigned to
the control arm. We assume that G distinct patient subgroups have been defined according
to multivariate patient characteristics and that Gi is a variable which indicates membership
in one of the G subgroups. For example, suppose that patient subgroups have been formed
on the basis of age (young/old) and sex (male/female) combinations. In this case, we would
have G = 4 subgroups to represent each age/sex combination, and Gi would be a variable
indicating to which of the four categories the ith individual belongs.
Subgroup analyses that only examine the primary outcome typically utilize a collection
of summary statistics which measure treatment effectiveness in each subgroup considered.
Such summary statistics are usually computed for marginally defined subgroups (i.e., sub-
groups defined by looking at one variable at-a-time) or subgroups which are defined accord-
ing multivariate characteristics. In our analysis of bivariate patient outcomes, we require
that one compute a pair of summary statistics (Dawg, Uawg) for each AE-treatment arm
combination within each subgroup. The summary statistic Dawg is the number of PEs that
are observed to occur among the patients in subgroup g (g = 1, . . . , G), treatment arm a
(a = 0, 1), and have AE status w (w = 0, 1). Similarly, Uawg is the total follow-up time
for the group of patients that are in subgroup g, treatment arm a, and have AE status w.
In addition to (Dawg, Uawg), we require that one compute the summary statistics Vag for
each treatment arm-subgroup combination. The summary statistic Vag is the total number
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of AEs observed for those patients in subgroup g and treatment arm a. More formally,
(Dawg, Uawg) and Vag are defined in terms of the individual-level responses as
Dawg =
n∑
i=1
δiI(Ai = a)I(Wi = w)I(Gi = g)
Uawg =
n∑
i=1
YiI(Ai = a)I(Wi = w)I(Gi = g)
Vag =
n∑
i=1
WiI(Ai = a)I(Gi = g)
Table 2 shows the summary statistics (Dawg, Uawg, Vag) from the SPRINT trial using
G = 8 subgroups. These 8 subgroups were formed by looking at all possible combinations
of the following three baseline patient variables: chronic kidney disease (Yes/No), age
(≥ 75/ < 75), and sex (male/female).
Subgroup Standard Treatment Intensive Treatment
CKD Sex Age (D01g, U01g) (D00g, U00g) V0g (D11g, U11g) (D10g, U10g) V1g Ng
No < 75 Male (3, 92.00) (96, 5546.11) 29 (10, 174.05) (54, 5446.53) 61 3528
Yes < 75 Male (3, 48.41) (28, 1364.73) 16 (5, 103.15) (25, 1227.70) 32 858
No ≥ 75 Male (1, 19.57) (46, 1277.47) 8 (1, 57.67) (26, 1265.94) 19 913
Yes ≥ 75 Male (6, 40.00) (47, 977.71) 15 (7, 88.31) (38, 974.85) 31 730
No < 75 Female (0, 40.08) (31, 2641.97) 13 (0, 67.47) (25, 2705.38) 20 1706
Yes < 75 Female (2, 42.41) (12, 948.66) 14 (4, 50.23) (16, 1000.35) 16 617
No ≥ 75 Female (0, 37.84) (16, 835.07) 12 (1, 60.98) (18, 778.16) 20 568
Yes ≥ 75 Female (3, 30.81) (25, 612.09) 11 (2, 66.44) (11, 634.87) 21 441
Table 2: SPRINT trial: Summary statistics for the 8 subgroups defined by the baseline
variables: chronic kidney disease (CKD), age, and sex. The summary statistics Uawg are
computed using time measurements in years, but these are not provided here.
3.2 Distribution of Key Summary Statistics and Joint Distribu-
tion of Primary and Adverse Events
In our analysis, we assume the number of observed events Dawg follows a Poisson distribu-
tion whose mean depends on the total follow-up time Uawg and the hazard rate λawg within
the subset of patients with the (a, w, g) combination of treatment arm a, AE status w, and
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subgroup g. Specifically, given λawg, we assume Dawg is distributed as
Dawg|λawg ∼ Poisson(λawgUawg).
The assumed Poisson distribution for the summary statistics Dawg is equivalent to assuming
that, at the individual level, the time-to-failure Ti of the primary event follows an expo-
nential distribution with rate λawg. More specifically, the likelihood function that results
from assuming Dawg|λawg ∼ Poisson(λawgUawg) is the same (ignoring constant terms) as
the likelihood function that results from assuming that
Ti|Wi = w,Ai = a,Gi = g ∼ Exponential(λawg).
To fully define the joint distribution of the time-to-primary event Ti and the AE indi-
cator Wi given treatment arm and subgroup information, we now only need to specify the
conditional distribution of Wi given Ai and Gi. Here, we assume that Wi is a Bernoulli
random variable with a success probability pag that depends on the treatment arm and
subgroup. This implies the distribution of Vag is given by
Vag|pag ∼ Binomial(nag, pag),
where nag is the number of individuals in treatment arm a and subgroup g.
The parameters (λawg, pag) characterize the joint distribution of the primary and adverse
event within the subgroup g and treatment arm a. To see why this is the case, note that
the joint probability P (Ti > t,Wi = w|Ai = a,Gi = g) may be expressed as
Sag(t, w) = P (Ti > t,Wi = w|Ai = a,Gi = g)
= P (Ti > t|Wi = w,Ai = a,Gi = g)P (Wi = w|Ai = a,Gi = g)
= e−λawgtpwag(1− pag)
1−w.
Comparing S1g(t, w) and S0g(t, w) for each subgroup enables one to compare the effect of
the treatment on altering the risk-benefit profiles of patients in subgroup g.
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4 Modeling Subgroup Effects
4.1 Regression Models for Subgroup Parameters
As described above, our model for the summary measures (Dawg, Uawg, Vag) depends on
the collection of hazard rate parameters λawg and the AE probabilities pag. Because the
number of parameters is potentially quite large, models which induce shrinkage are needed
to produce stable estimates of these quantities. We describe a general regression models for
λawg and pag which allow for shrinkage and allow for one to include information regarding
how the subgroups parameters are related. In Sections 4.1.1-4.1.3, we describe three specific
regression models, and in Section 4.2 we describe our prior specification for the parameters
of two of these regression models.
We consider a regression setting with design matrices X and Z for the hazard rate
parameters λawg and AE probabilities pag respectively. The matrices X and Z are G× qx
and G× qz respectively, and x
T
g and z
T
g denote the g
th rows of X and Z respectively. The
hazard rate parameters λawg and the adverse-event probabilities are related to xg and zg
via
log(λawg) = x
T
g βaw and logit(pag) = z
T
g γa,
where logit(x) = log{x/(1− x)}. Here βaw is the qx × 1 vector βaw = (βaw,1, . . . , βaw,qx)
T ,
and γaw is the qz × 1 vector γa = (γa,1, . . . , γa,qz)
T . In total, this regression model involves
4qx + 2qz parameters. We describe a few possible ways of choosing X and Z below.
4.1.1 Example 1: Saturated Model.
In this model, the number of regression parameters is equal to the number of summary
statistics. The design matrices X and Z are assumed to be equal to the G × G identity
matrix, and each βaw, γa are assumed to be G × 1 vectors. This means that, for any
combination of (a, w, g), we have
log(λawg) = βaw,g and logit(pag) = γa,g.
9
In this model, there is no regression structure linking the parameters λawg or the parameters
pag together in such a way that more strength is borrowed between subgroups which share
a greater number of patient characteristics. Rather, the λawg and pag are treated separately
with no additional information used to indicate the relationships among the subgroups.
4.1.2 Example 2: Additive Model.
In this model, the values of λawg and pag are determined additively from the variables
comprising subgroup g. This approach is analogous to the Dixon and Simon model for
subgroup analysis (see e.g., Dixon & Simon (1991), Jones et al. (2011), or Henderson et al.
(2016)). The number of regression parameters in this model are determined by both the
number of patient variables and the number of levels within each one of these variables.
To define the additive model, we suppose that the G subgroups are formed by p patient
variables, and the jth patient variable has levels 1, . . . , pj. If we consider modeling λawg for
subgroup g, it is necessary to know the levels of each of the patient variables comprising
subgroup g. If the level of the jth variable in subgroup g is denoted by g(j), then
log(λawg) = βaw,1 +
p∑
j=1
pj∑
k=2
1{g(j) = k}βaw,Qj+k
logit(pag) = γa,1 +
p∑
j=1
pj∑
k=2
1{g(j) = k}γa,Qj+k, (1)
where Q1 = 0 and Qj = 1 − j + p1 + . . . + pj−1 for j > 1. As an illustration of (1),
consider an example where four subgroups are formed from the combinations of the patient
variables of age (young/old) and sex (male/female) and that male and young denote the
first levels of the age and sex variables respectively. Suppose further that we label the
four subgroups in the following manner: subgroup 1 denotes male/young (i.e., g(1) = 1,
g(2) = 1), subgroup 2 denotes male/old (i.e., g(1) = 1, g(2) = 2), subgroup 3 denotes
female/young (i.e., g(1) = 2, g(2) = 1), and subgroup 4 denotes female/old (i.e., g(1) = 2,
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g(2) = 2). In this case, the λawg would be expressed as
(Male/Young) log(λaw1) = βaw,1
(Male/Old) log(λaw2) = βaw,1 + βaw,2
(Female/Young) log(λaw3) = βaw,1 + βaw,3
(Female/Old) log(λaw4) = βaw,1 + βaw,2 + βaw,3,
and the relation between the pag and (γa,1, γa,2, γa,3) would be expressed similarly.
4.1.3 A Proportional Hazards Model
An even more parsimonious approach than the regression models discussed above is to
assume instead that the hazard ratios λa1g/λa0g do not vary across subgroups. Under this
assumption, the parameters (λa0g, pag) would be modeled as
log(λa0g) = x
T
g βa and logit(pag) = z
T
g γa,
and the hazard rates λa1g would be obtained from the AE-free hazard rates λa0g via λa1g =
φλa0g where φ is the constant hazard ratio. With this proportional hazards assumption,
there are now 2qx + 2qz + 1 regression parameters rather than the 4qx + 2qz parameters
required for the regression models discussed in Sections 4.1.1 and 4.1.2. While this approach
makes a quite restrictive assumption about how the AE-present and AE-free hazard rates
are related, this could be a useful approach if the proportional hazards assumption λa1g =
φλa0g is justifiable and is seen to be reasonable in light of model diagnostics.
4.2 Prior Specification
4.2.1 Prior for Saturated Model.
For each value of (a, w), we assume the parameters βaw,g = log(λawg) are drawn from a
common normal distribution with mean µaw and variance τ
2
aw
βaw,1, . . . , βaw,G|µwa, τaw ∼ Normal(µaw, τ
2
aw).
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The distribution of all the parameters βaw,g;w = 0, 1; a = 0, 1; g = 1, . . .G depends only
on the following four vectors: µ0 = (µ00, µ10)
T , µ1 = (µ01, µ11), τ 0 = (τ00, τ10)
T , and
τ 1 = (τ01, τ11)
T . The mean vector µa for treatment arm a is assumed to have the following
bivariate normal distribution
µa ∼MVN2
(
0
0

 ,

 σ2µ,a σµ,aρ2µ,a
σ2µ,aρµ,a σ
2
µ,a


)
,
where Z ∼ MV N2(µ,Σ) means that Z has a bivariate normal distribution with mean
vector µ and covariance matrix Σ. Similarly, the distribution for τ a on the log scale is
assumed to be given by
log(τ a) ∼MV N2
(log(1/2)
log(1/2)

 ,

 σ2τ,a σ2τ,aρτ,a
σ2τ,aρτ,a σ
2
τ,a

).
For the correlation parameters ρµ,a and ρτ,a, we assume that ρµ,a ∼ Uniform(−1, 1) and
ρτ,a ∼ Uniform(−1, 1) for each a. Our prior distribution for the γa,g is similar to the prior
for the βaw,g. Specifically, we start by assuming that
γa,1, . . . , γa,G|µa,γ, τa ∼ Normal(µa,γ, τ
2
a,γ).
We then assume that µa,γ ∼ Normal(log(1/2), σ
2
µ,a,γ) for a = 0, 1, and we assume that
log(τa,γ) ∼ Normal(0, σ
2
τ,a,γ) for a = 0, 1.
In total, there are 8 hyperparameters in this model. These are: σµ,0, σµ,1, στ,0, στ,1,
σ2µ,0,γ , σµ,1,γ , στ,0,γ, and στ,1,γ . Our default choice is to set σµ,0 = σµ,1 = σµ,0,γ = σµ,1,γ = 100
and to set στ,0 = στ,1 = στ,0,γ = στ,1,γ = 1. Our justification for these default settings is
discussed in more detail below.
Our prior specification implies the log(λawg), g = 1, . . . , G are drawn from a common
normal distribution with mean µaw and variance τ
2
aw. Because it is difficult to specify a
range of reasonable values for the median of log(λawg), g = 1, . . . , G, we assign µaw a vague
prior distribution by setting σµ,a = 100, for a = 0, 1. A similar justification can be made
for setting σµ,a,γ = 100. Turning now to the variation in log(λawg) we note that, for any
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pairs of subgroup indices j, k, the distribution of the hazard ratio (given τaw) λawj/λawk
follows a log-normal distribution with parameters 0 and 2τ 2aw. Our prior distribution for
τaw is based on the observation that the hazard ratio is most likely between 1/4 and 4.
Because P{1
4
≤ λawj/λawk ≤ 4|τaw} ≈ 1 − 2Φ(−1/τaw), this means that this approximate
probability is greater than 0.68 whenever τaw ≤ 1 and greater than 0.95 whenever τaw ≤ 1/2.
We want to choose a prior for τaw such that P{
1
4
≤ λawj/λawk ≤ 4|τaw} is fairly large for the
most probable values of τaw. This can be done by assuming that τaw follows a log-normal
distribution with parameters log(1/2) and 1 (i.e., setting στ,a = 1). This means that τaw
has a median of 1/2 and that the probability that τaw is less than 2.6 is approximately
0.95. A similar justification can be made for setting στ,a,γ = 1.
4.2.2 Prior for Additive Model.
We assign vague priors to the intercept terms βaw,1 and γa,1. Specifically, it is assumed that
βaw,0 ∼ Normal(0, σ
2
0,β) and γa,0 ∼ Normal(0, σ
2
0,γ),
with σ0,β and σ0,γ set to default values of σ0,β = 100 and σ0,γ = 100.
The hierarchical model for the remaining regression coefficients βaw,j, j = 1, . . . ,
∑
pj−
(p − 1) and γa,j , j = 2, . . . ,
∑
pj − (p − 1) is the same as that used for the regression
coefficients in the saturated model. That is, we assume that
βaw,1, . . . , βaw,qx ∼ Normal(µaw, τ
2
aw)
γa,1, . . . , γa,qz ∼ Normal(µa,γ , τ
2
a,γ),
where qx = qz =
∑p
j=1 pj − (p − 1). The prior distributions and default hyperparameters
for µa,γ, τa,γ and the four vectors µ0 = (µ00, µ10)
T , µ1 = (µ01, µ11), τ 0 = (τ00, τ10)
T , and
τ 1 = (τ01, τ11)
T are exactly the same as described for the saturated model.
4.2.3 Posterior Computation
The Bayesian bivariate subgroup models proposed here can be easily computed using STAN
software. With STAN, we have implemented both the saturated and additive models. In
13
our analysis of the SPRINT trial, we used 4, 000 posterior draws obtained from four chains
each having 1500 iterations with the first 500 iterations treated as burn-in. The code for im-
plementing our models can be obtained from our website: http://hteguru.com/index.php/bbsga/
5 Measures of Risk-Benefit
5.1 Heterogeneity in Joint Binary Outcomes
A natural bivariate outcome of interest is survival past a specified time point κ0 coupled
with an indicator of whether or not an AE occurred during the follow-up period. For this
bivariate outcome, there are four possible results: survival past κ0/no AE occurs, survival
past κ0/AE occurs, failure before κ0/no AE occurs, and failure before κ0/AE occurs. The
subgroup-specific posterior probabilities of each of these four outcomes may be obtained
from the models detailed in Sections 3 and 4. The differences in these probabilities between
treatment arms provide a measure by which to compare how treatment influences the
probability of experiencing each of these four outcomes. If we define the function Fag(t, w)
as
Fag(t, w) = P (Ti ≤ t,Wi = w|Ai = a,Gi = g)
= (1− exp(−λawgt))p
w
ag(1− pag)
1−w,
the differences in these four joint probabilities may be expressed as
θg1 = S1g(κ0, 0) − S0g(κ0, 0)
θg2 = S1g(κ0, 1) − S0g(κ0, 1)
θg3 = F1g(κ0, 0) − F0g(κ0, 0)
θg4 = F1g(κ0, 1) − F0g(κ0, 1)
If the PE is regarded as more undesirable than the adverse event, then the parameters
(θg1, θg2, θg3, θg4) may be thought of as being ordered according to the desirability of the
associated outcome. Specifically, θg1 represents the difference in the probability of achiev-
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ing the most desirable outcome, namely remaining both PE and AE free until time κ0.
Similarly, θg2 represents the difference in the probability of achieving the second most de-
sirable outcome, namely remaining free from the PE until time κ0 while experiencing an
AE at some time before κ0. The parameter θg3 represents the difference in probability of
experiencing the PE while not experiencing the AE, and θg4 represents the difference in
probability of experiencing both the primary and adverse event before time κ0. It is worth
noting that
∑
4
j=1 θgj = 0 for each g. That is, if the treatment increases the probability of
one outcome relative to control, it must decrease the probability of another outcome (or
group of outcomes) by a corresponding amount.
Using the SPRINT trial data with the 8 subgroups defined by chronic kidney disease
status, age, and sex, Figure 1 plots the posterior means of (θg1, θg2, θg3, θg4). The posterior
quantities shown in Figure 1 were computed using the saturated model. For each of the
forest plots in Figure 1, the solid vertical line represents the average value of the posterior
means of θgj across subgroups, i.e.,
1
G
∑
g θˆgj where θˆgj is the posterior mean of θgj . The
quantity θˆj,ov =
1
G
∑G
g=1 θˆgj can be thought of as an estimate of the overall treatment
effect for PE-AE category j. Looking at Figure 1, the estimated overall treatment effect
is negative for PE-AE categories 1 and 3 and is positive for categories 2 and 4 though the
magnitude of the estimates for categories 3 and 4 is very small. Specifically, the values of
θˆj,ov were θˆ1,ov = −0.019, θˆ2,ov = 0.025, θˆ3,ov = −0.007, and θˆ4,ov = 0.001. These values
suggest the intensive treatment increases the probability of 3-year PE-free survival while
experiencing a treatment-related SAE, and it reduces the probability of experiencing a PE
without an SAE. However, the intensive treatment also appears to reduce the probability
of remaining both PE and SAE free for 3 years by an a similar amount to the increase
in the probability of outcome 2. Comparing the estimates θˆ1,ov, θˆ2,ov, and θˆ3,ov leads to
a somewhat ambiguous picture about the effect of the intensive treatment on improving
patient outcomes. A more complete evaluation of the risk/benefit effect of the intensive
treatment would involve consideration of patients’ “baseline bivariate risk”. Specifically, the
baseline bivariate risk refers to the probability of each PE-AE combination occurring under
the control arm. Such baseline information would be useful in assessing the meaningfulness
of any change θgj that the treatment induces on the probability of outcome j.
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Figure 1: SPRINT trial with eight subgroups defined by chronic kidney disease (CKD),
age, and sex. Posterior means and associated credible intervals using the saturated model
are plotted for θg1, θg2, θg3, θg4. Note that the range of the x-axis can differ across θg1, θg2,
θg3, θg4. For each j, the vertical line is placed at θˆj,ov, the average value of the posterior
means θˆgj across subgroups.
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Turning now to the variation in θgj across subgroups, two subgroups from Figure 1 seem
to stand out. The more prominent of these is the no-CKD/Age < 75/Female subgroup.
In this subgroup, the 95% credible interval for θg2 does not cover the overall treatment
effect estimate θˆ2,ov, and the credible interval for θg1 nearly does not cover θˆ1,ov. This
suggests the effect of the intensive treatment on altering a patients’ PE-AE outcome profile
is somewhat different in the no-CKD/Age < 75/Female subgroup than in the broader
population represented by the trial. Specifically, compared to other groups in the trial, the
intensive treatment for those in the no-CKD/Age < 75/Female subgroup had almost no
effect on any of the PE-AE probabilities as the estimates θˆgj for this subgroup were much
closer to zero when compared with their overall counterparts θˆj,ov. Another subgroup worth
highlighting is the no-CKD/Age < 75/Male subgroup. Though not as extreme as the no-
CKD/Age < 75/Female subgroup, the estimates of θg1 and θg2 are modestly closer to zero
than the average values of these parameters, and while the credible intervals for these
parameters still covered θˆ1,ov and θˆ2,ov, most of the mass of these credible intervals were to
the right and left of θˆ1,ov and θˆ2,ov respectively.
Figure 2 displays posterior estimates of (θg1, θg2, θg3, θg4) from the additive model. One
notable difference between the additive and the saturated model is in the overall estimates
θˆ1,ov and θˆ3,ov. Specifically, the estimate θˆ1,ov was much closer to zero in the additive
model than in the saturated model. As with the saturated model, both the no-CKD/Age
< 75/Female and no-CKD/Age < 75/Male subgroups stand out in the additive model due
to lower magnitudes of θg2. The estimated values of θg1 for the no-CKD/Age < 75/Female
subgroup is actually quite similar to those from the saturated model. However, due to
differences between the saturated and additive models in the overall estimate θˆ1,ov, the
value of θg1 for this subgroup does not appear different than the estimated overall value of
this parameter.
5.2 Comparing Utilities across Subgroups
While forest plots of θg1, . . . , θg4 can be useful for examining variability in the effect of treat-
ment on altering patients’ risk-benefit profiles, interpreting such graphs can be somewhat
challenging. Converting the bivariate outcomes into a composite score by weighting each
17
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Figure 2: SPRINT trial with eight subgroups defined by chronic kidney disease (CKD),
age, and sex. Posterior means and associated credible intervals using the additive model
are plotted for θg1, θg2, θg3, θg4. For each j, the vertical line is placed at θˆj,ov, the average
value of the posterior means across subgroups.
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outcome allows one to report heterogeneity with respect to a univariate score. Weighting
methods for assessing risk-benefit have been described by a number of researchers includ-
ing, for example, Chuang-Stein (1994). We consider here two approaches for weighting
joint patient outcomes.
A direct way of combining θg1, . . . , θg4 to produce a univariate score would be to compute
θ˜g = b1θg1 + b2θg2 + b3θg3 + b4θg4 (2)
for weights b1, . . . , b4. Assuming that a patient receives a utility of bj when experiencing
outcome j, θ˜g represents the difference in expected utility between treatments for those in
subgroup g. In other words, if one defines a composite outcome where a patient is assigned
a composite of score of bj according to , then θ˜g represents the subgroup-specific expected
difference in this composite outcome.
Rather than weight joint binary outcomes as is done in computing θ˜g, an alternative
is to incorporate the survival time directly into the composite outcome. We define such a
composite score Hi which, for the i
th patient, we define as
Hi = b1Wimin{Ti, τ}+ b2(1−Wi)min{Ti, τ}, (3)
where τ represents a truncation point that represents a follow-up period of interest. The
composite measure Hi may be viewed as an outcome whose expectation is a type of
weighted restricted mean survival time (RMST) (see e.g., Royston & Parmar (2013)). We
use min{Ti, τ} rather than Ti to reduce the impact of model extrapolation beyond the
follow-up period of interest (0, τ). With the measure Hi, a patient receives a weight of
b2 for each time unit of PE-free survival assuming he/she did not experience an AE over
the time interval (0,min{Ti, τ}). Likewise, a patient receives a weight of b1 for each unit
of PE-free survival time assuming he/she did experienced an adverse event at some point
in the time interval (0,min{Ti, τ}). The composite outcome Hi bears some resemblance
to the Q-TWist measure described in Gelber et al. (1989) though Hi does not explicitly
distinguish between time with toxicity and time without toxicity.
The expectation of the composite outcome Hi conditional on subgroup and treatment
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Figure 3: SPRINT trial with eight subgroups defined by chronic kidney disease (CKD),
age, and sex. Utility analysis using the saturated model and composite outcome measure
Hi. Posterior means and credible intervals for ηg are shown for each subgroup. The solid
vertical line is placed at the average value of the posterior means of ηg across subgroups.
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arm information is given by
E[Hi|Ai = a,Gi = g] =
b1pag(1− e
−τλa1g)
λa1g
+
b2(1− pag)(1− e
−τλa0g)
λa0g
.
Subgroup-specific treatment effects ηg relative to this measure may then be defined as the
difference in the expectation of Hi in the treatment arm vs. the expectation of Hi in the
control arm
ηg = E[Hi|Ai = 1, Gi = g]− E[Hi|Ai = 0, Gi = g]. (4)
Figure 3 shows estimates of the treatment effects ηg using the saturated model and two
choices of weights (b1, b2). For each choice of weights, we set b2 = 1, and we set b1 to 0.8 and
0.5 for the left-hand and right-hand plots respectively. When b2 = 1, b2 may be interpreted
as the proportion of value that one receives from a unit of extra life when an AE is known
to occur as compared to the value of an extra unit of life when no AE occurs. Hence,
a value of b1 very close to one implies that AE-free survival and AE-occurring survival
are valued similarly while values of b1 much lower than one imply that AE-free survival is
valued much more highly than AE-occurring survival.
It is interesting to note that the younger subgroups (i.e., age < 75) tend to consistently
receive less benefit treatment for both choices of weights. Indeed, all of the younger sub-
groups have posterior means less than the average value of the posterior means ηˆg. In Figure
3, two subgroups stand out in terms of being different than the average value of ηg across
subgroups. These are the no-CKD/Age < 75/Female and yes-CKD/Age < 75/Female
subgroups. Both of these subgroups do not appear to benefit when using either choice
of weights to compute Hi. This is not that surprising for the no-CKD/Age < 75/Female
subgroup as the four-outcome subgroup analysis from Figure 1 suggested the intensive
treatment had very little impact in changing the probabilities of any of the four outcomes.
Similarly, the point estimates from Figure 1 also suggested that the treatment had little
effect on the yes-CKD/Age < 75/Female subgroup though the posterior uncertainty for
these estimates was much greater than for the no-CKD/Age < 75/Female subgroup. In-
terestingly, the no-CKD/Age < 75/Male subgroup did not show clear evidence of having a
worse treatment effect ηg than the average from the other subgroups.
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5.3 Heterogeneity in the Probability of Outcome Improvement
While using weights to create univariate composite measures can be useful, it is often
difficult to justify a particular choice of weights in an analysis. An alternative to weighting
is to order the outcomes according to their desirability and to use the probability of outcome
improvement as the treatment effect to be measured. An advantage of approaches which
rely on ordering outcomes (see e.g., Claggett et al. (2015) or Follmann (2002)) is that they
do not require that one assign numerical values to each outcome but only require that one
be able to order outcomes according to their desirability.
We consider here an ordering-based definition of treatment effect that compares the
outcomes of two patients randomly drawn from each treatment arm. Specifically, we con-
sider two treatment-discordant patients i and j (say Ai = 1 and Aj = 0) which are chosen
randomly from subgroup g. If we could observe the failure times Ti and Tj along with Wi
and Wj, it would be possible to determine which patient had the superior outcome. That
is, we could construct a function O(·, ·|·, ·) such that O(Ti,Wi|Tj,Wj) = 1 when outcome
(Ti,Wi) is superior to (Tj,Wj) and O(Ti,Wi|Tj,Wj) = 0 otherwise. While there are many
ways of choosing O(Ti,Wi|Tj ,Wj), Table 3 describes our approach for ordering pairs of
bivariate outcomes. Here, we rely on an indifference parameter δ > 0 which represents the
additional gain in survival that would be needed to compensate for suffering from the AE.
For example, suppose that Wi = 1 and Wj = 0 and that the indifference parameter is set
to δ = 0.5. In this case, patient i would need an at least 50% longer survival time than
patient j in order for the outcome of patient i to be preferable to the outcome of patient j.
Outcomes Preferred Treatment
Ti > Tj(1 + δ) Wi = 1,Wj = 0 A = 1
Ti ≤ Tj(1 + δ) Wi = 1,Wj = 0 A = 0
Tj > Ti(1 + δ) Wi = 0,Wj = 1 A = 0
Tj ≤ Ti(1 + δ) Wi = 0,Wj = 1 A = 1
Ti > Tj Wi = 1,Wj = 1 A = 1
Ti > Tj Wi = 0,Wj = 0 A = 1
Ti ≤ Tj Wi = 1,Wj = 1 A = 0
Ti ≤ Tj Wi = 0,Wj = 0 A = 0
Table 3: Our approach for comparing two joint outcomes (Ti,Wi) and (Tj ,Wj) assuming
that Ai = 1 and Aj = 0.
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Using the outcome orderings described in Table 3, we define the subgroup-specific treat-
ment effects φg as
φg = 2P
{
O(Ti,Wi|Tj ,Wj) = 1 | Ai = 1, Aj = 0, Gi = g,Gj = g
}
− 1. (5)
The parameter φg represents the probability that patient i has a superior outcome to patient
j minus the probability that patient j has a superior outcome to patient i when assuming
both patients i and j belong to subgroup g. Hence, φg = 1 when patients in subgroup g
are sure to benefit from treatment, and φg = −1 when patients in subgroup g are certain
to be harmed by treatment. Note that φg is a function of the subgroup-specific parameters
λawg and pag and thus one may easily obtain draws from the posterior distribution of φg by
transforming samples from the posterior distribution of (λawg, pag). More specifically, φg is
related to the model parameters via
φg = 2
[ λ00gp1g(1− p0g)
λ11g(1 + δ) + λ00g
+
λ01g(1− p1g)p0g
λ10g/(1 + δ) + λ01g
+
λ00g(1− p1g)(1− p0g)
λ10g + λ00g
+
λ01gp1gp0g
λ11g + λ01g
]
−1.
Figure 4 plots the posterior means of φg for each subgroup using both the saturated
and additive models. For this analysis, we set δ to δ = 0.2. This means that an individual
receiving the intensive treatment would need at least 1.2 times as much PE-free survival
as under the standard treatment in order to be “compensated” for the fact that he/she
would experience a treatment-related SAE under the intensive treatment while remaining
SAE-free under the standard treatment arm. In Figure 4, the “overall” treatment effects
are represented by the solid vertical lines. These are computed as 1
G
∑G
g=1 φˆg where φˆg is
the posterior mean of φg. The overall treatment effect estimates were 0.12 and 0.13 for the
saturated and additive models respectively.
As shown in Figure 4, there is less clear variability across subgroup when using the
treatment effect φg. Specifically, all the credible intervals for both the saturated and ad-
ditive models cover the average value of the posterior means φˆg. It is interesting to note
that, on this scale, the estimated treatment effect for the no-CKD/Age < 75/Female sub-
group is now very close to the estimated overall treatment effect which seems to stand in
contrast to the results in Sections 5.1 and 5.3. While the width of the credible intervals in
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Figure 4: Sprint Trial: Posterior means of treatment effects φg with δ = 0.2 (see Table 3).
Posterior means and credible intervals for φg are shown for both the saturated and additive
models. The solid vertical lines are placed at the overall treatment effect estimates i.e,
1
G
∑G
g=1 φˆg, where φˆg is the posterior mean of φg.
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both the saturated and additive models prevents us from making any strong conclusions
about this subgroup, it is worthwhile to note how the prominence of a treatment-covariate
interaction can change when the treatment effect scale is changed. The differences between
the saturated and additive models for the no-CKD/Age ≥ 75/Female and yes-CKD/Age
≥ 75/Female subgroups is also noteworthy. In addition to much greater shrinkage with the
additive model, the difference between the estimates of φg in these 2 subgroups changes sign
between the saturated and additive models. This is due to the more structured borrowing
of information among subgroups that is enabled by the additive model. Specifically, much
information is shared among subgroups carrying the same CKD status with the no-CKD
subgroups being consistently shrunken towards a larger value than the yes-CKD subgroups.
6 Model Checking and Diagnostics
Our approach assumes that, conditional on an AE indicator, survival follows an exponential
distribution within each subgroup/treatment arm combination. We feel that such a simple
parametric approach is needed due to the potentially large number of “cells” that arise
from the number of subgroup/treatment arm/AE combinations where the sparse amount
of within-cell data precludes more ambitious modeling. Despite this, our model treats
patient survival as arising from a type of mixture-of-exponentials distribution and such a
mixture can often provide a good fit to the observed overall survival patterns.
Posterior predictive checks (Meng (1994)) are a useful tool for assessing the goodness-
of-fit of a Bayesian model. Such checks are performed by first simulating outcomes from
the posterior predictive distribution and computing a test statistic (or a collection of test
statistics) of interest for each simulation replication. The distribution of the computed
test statistics across posterior predictive draws is then compared with the observed value
of this test statistic. An observed value of the test statistic that seems “typical” with
respect to the posterior predictive distribution of this test statistic is an indication that the
model provides a good fit or, at least, is not clearly deficient in some way. Figure 5 shows
treatment-specific estimated survival curves from 50 draws from the posterior predictive
distribution. Here, the test statistics of interest are the treatment-specific Kaplan-Meier
estimates. As shown in Figure 5, the Kaplan-Meier estimates for the observed data seem
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Figure 5: SPRINT trial: Draws from the posterior predictive distribution for the saturated
model. Kaplan-Meier estimates for the primary outcomes from the observed data are
plotted in solid red. Kaplan-Meier estimates from fifty draws from the posterior predictive
distribution are plotted in grey.
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typical when compared with the collection of Kaplan-Meier estimates from the 50 posterior
predictive draws. Indeed, for both treatment arms, the observed Kaplan-Meier estimates
are roughly centered among the posterior predictive survival curves, and the shapes of
the posterior predictive survival curves largely resemble the linear shape of the observed
Kaplan-Meier estimates.
Beyond graphical displays of survival, one can use univariate test statistics and posterior
predictive p-values as a way of more formally assessing goodness-of-fit. Posterior predictive
p-values represent the probability that hypothetical replications of the test statistic from
the posterior predictive distribution is more extreme than the observed value of the test
statistic. It is often recommended to try test statistics which are not directly modeled by the
probability model used (Gelman et al. (2014)). Figure 6 displays the posterior predictive
distributions of the restricted mean survival time (RMST) using both the saturated and
additive models. For the saturated model, the two-sided posterior predictive p-values are
0.30 and 0.38 for the standard and intensive treatment arms respectively. For the additive
model, the two-sided posterior predictive p-values are 0.28 and 0.40 for the standard and
intensive treatment arms respectively. These relatively large posterior predictive p-values
do not indicate that either model has a serious flaw.
Predictive Criterion Additive Model Saturated Model
DIC 12853.3 12863.4
WAIC 12861.9 12865.2
Table 4: Comparisons of the saturated and additive models using different information
criteria.
Information criteria can be used to compare models such as the saturated and additive
models that have differing number of parameters. The use of information criteria can be
helpful whenever model checking procedures do not clearly show that one of the models
is inadequate or when there is no strong a priori reason for favoring one model over the
other. Two well-known information criteria that can be computed for Bayesian hierarchical
models are the deviance information criterion (DIC) (Spiegelhalter et al. (2002)) and the
widely-applicable information criterion (WAIC) (Watanabe (2010)). Both of these criterion
are found by adding a penalty to negative two times the log-likelihood function evaluated
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Figure 6: SPRINT trial: Posterior predictive checks. Samples from the posterior predictive
distribution of the RMST (by treatment arm) using both the saturated and additive models.
Solid vertical lines are placed at the observed values of the RMST.
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at the posterior mean of the model parameters. The penalty is determined by the model
degrees of freedom which are computed differently by DIC and WAIC. Lower values of both
the DIC and WAIC imply better model performance.
As shown in Table 6, the additive model had a DIC which was roughly 10 less than
the DIC of the saturated model. Differences in the DIC of less that 3 − 5 are often not
considered meaningful (see e.g., Carlin & Louis (2009)) so this difference of 10 provides
moderate support in favor of the additive model. Moreover, the additive model may be
especially preferred if a parsimonious model is desired. In contrast to the DIC, the satu-
rated and additive models are much closer when using WAIC as the comparison measure.
Nevertheless, a difference of roughly 4 in WAIC value still provides mild support in favor
of the additive model. Thus, for the SPRINT data, there does not seem to be a good
justification for using the saturated model as the log-likelihood (evaluated at the posterior
mean of the parameters) for both models is roughly the same while the saturated model
requires considerably fewer model parameters.
7 Discussion
In this article, we have described a Bayesian approach for performing subgroup analysis
with respect to both a primary and safety endpoint and have detailed its use in generating
relevant within-subgroup risk-benefit measures. A key feature of our approach is that the
benefit-safety endpoints are modeled jointly rather than used to perform separate subgroup
analyses of benefit and safety.
Summary assessment of risks and benefits, i.e. combining the multiple risks and benefit
outcomes into a single utility measure, is a challenging problem. In section 5.2 we have
provided a few reasonable options, Eqs. 2, 4, 5. Other summary measures are certainly
possible. It should be remarked that both the primary and safety endpoints used in the
SPRINT trial are themselves composite endpoints. Hence, it may be worth decomposing
these composite measures further for a more thorough assessment of benefit and risk (e.g.,
death and other cardiac events are treated the same).
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